Special Issue

Antimicrobial Treatment Challenges in Gastroenterology and Malignancy Associated Infections: Current Trends, Debates and Future Perspectives

Message from the Guest Editors

In an era of widespread clinical guideline use, physicians face many challenges when using antimicrobial treatments, as their optimal use is often influenced by local factors such as drug availability, antibiotic resistance, local habits, and institutional policy. This Special Issue will provide answers to these debates and challenges according to guideline adjustments to local practices, providing useful information for wider clinical use. Another main goal of this Special Issue is to discuss current questions regarding and solutions for overcoming antibiotic resistance. We invite colleagues, especially from the fields of gastroenterology, clinical oncology, and hematology, to submit articles. Articles from other specialties, as well as review articles discussing debates about antimicrobial treatment, are welcome.

Guest Editors

Dr. Ibolya Czegle

Department of Internal Medicine and Hematology, Faculty of Medicine, Semmelweis University, H-1085 Budapest, Hungary

Dr. Péter Birinyi

Department of Pharmacodynamics, Faculty of Pharmacy, Semmelweis University, H-1085 Budapest, Hungary

Deadline for manuscript submissions

30 April 2026



an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/259519

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

